OSLO/LONDON, 8 June 2022: EXACT Therapeutics AS ("EXACT-Tx", "the Company"
Euronext Growth: EXTX) held its Annual General Meeting on June 8th 2022 at 10:30
According to the record included as Appendix 1, 7,798,139 shares of a total of
29,992,167 issued shares and votes, corresponding to 26% of the total number of
voting shares in the Company, were represented at the general meeting.
All proposed resolutions were approved.
Please find enclosed the minutes of the meeting including appendices.
For more information, please contact:
Per Walday, CEO
Dominic Moreland, CFO
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.